瑞巴派特片联合雷贝拉唑钠肠溶片治疗慢性萎缩性胃炎的效果及安全性  

Efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis

作　　者：薛彦萍[1] 李晶[1] 侯云峰 Xue Yanping;Li Jing;Hou Yunfeng(Department of Gastroenterology,Central Hospital of Henan Energy Jiaozuo Coal Industry Group,Jiaozuo 454000,China)

机构地区：[1]河南能源焦作煤业集团中央医院消化内科,454000

出　　处：《中国实用医刊》2020年第4期100-103,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析瑞巴派特片与雷贝拉唑钠肠溶片治疗慢性萎缩性胃炎(CAG)的效果及安全性。方法抽取2013年1月至2018年1月河南能源焦作煤业集团中央医院收治的192例CAG患者,采用随机数字表法按1∶1比例分为对照组和观察组,每组96例。对照组给予雷贝拉唑钠肠溶片治疗,观察组给予瑞巴派特片联合雷贝拉唑钠肠溶片治疗,治疗4周,比较两组临床疗效,病理积分(腺体萎缩、肠上皮化生、异型增生),胃功能相关指标[胃泌素-17(GAS-17)、胃蛋白酶原Ⅰ(PGⅠ)、表皮生长因子(EGF)、内皮素-1(ET-1)],Hp根除率以及安全性情况。结果治疗后,观察组治疗总好转率为91.67%、Hp转阴率为80.21%,高于对照组(78.12%、62.50%),差异有统计学意义(P<0.05);两组腺体萎缩、肠上皮化生、异型增生各积分下降(P<0.05),观察组低于对照组(P<0.05);两组GAS-17、PGⅠ水平上升(P<0.05),EGF、ET-1水平下降(P<0.05),观察组优于对照组(P<0.05);两组治疗期间不良反应发生率比较差异未见统计学意义(P>0.05),安全性良好。结论瑞巴派特片与雷贝拉唑钠肠溶片联合治疗CAG效果明显,可有效缓解患者临床症状,调节胃功能相关指标水平,安全性较好。Objective To analyze the efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis (CAG).Methods A total of 192 CAG patients admitted to Central Hospital of Henan Energy Jiaozuo Coal Industry Group from January 2013 to January 2018 were included and randomly divided into control group and observation group according to the ratio of 1∶1, with 96 cases in each group. Control group was treated with rabeprazole sodium enteric-coated tablets, and observation group was given rebamipide tablets + rabeprazole sodium enteric-coated tablets, and they were treated for 4 weeks. The clinical efficacy, pathological scores (gland atrophy, intestinal metaplasia, dysplasia), gastric function-related indicators, including gastrin-17 (GAS-17), pepsinogen I (PGI), epidermal growth factor (EGF), endothelin-1 (ET-1), Hp eradication rate and safety were compared between the two groups.Results After treatment, the total improvement rate of treatment and negative conversion rate of Hp in observation group were significantly higher than those in control group, (91.67% and 80.21%) vs. (78.12% and 62.50%), the difference was statistically significant (P<0.05). The scores of gland atrophy, intestinal metaplasia and dysplasia were decreased in the two groups (P<0.05);the scores in observation group were lower than those in control group (P<0.05). The levels of GAS-17 and PGI were increased in the two groups (P<0.05) while the levels of EGF and ET-1 were significantly decreased (P<0.05), and the levels in observation group were superior to those in control group (P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05), with good safety.Conclusions Rebamipide tablets combined with rabeprazole sodium enteric-coated tablets has obvious effects on CAG, and it can effectively alleviate the clinical symptoms of patients and regulate the levels of gastric function-related indicators, with good safety

关 键 词：瑞巴派特片 雷贝拉唑钠肠溶片 慢性萎缩性胃炎 

分 类 号：R573[医药卫生—消化系统]